Microbeam Radiation Therapy (MRT) exploits tumour selectivity and normal tissue sparing with spatially fractionated kilovoltage X-ray microbeams through the dose volume effect. Experimental measurements with Ta 2 O 5 nanoparticles (NPs) in 9L gliosarcoma treated with MRT at the Australian Synchrotron, increased the treatment efficiency. Ta 2 O 5 NPs were observed to form shells around cell nuclei which may be the reason for their efficiency in MRT. In this article, our experimental observation of NP shell formation is the basis of a Geant4 radiation transport study to characterise dose enhancement by Ta 2 O 5 NPs in MRT. Our study showed that NP shells enhance the physical dose depending microbeam energy and their location relative to a single microbeam. For monochromatic microbeam energies below ∼70 keV, NP shells show highly localised dose enhancement due to the short range of associated secondary electrons. Low microbeam energies indicate better targeted treatment by allowing higher microbeam doses to be administered to tumours and better exploit the spatial fractionation related selectivity observed with MRT. For microbeam energies above ∼100 keV, NP shells extend the physical dose enhancement due to longer-range secondary electrons. Again, with NPs selectively internalised, the local effectiveness of MRT is expected to increase in the tumour. Dose enhancement produced by the shell aggregate varied more significantly in the cell population, depending on its location, when compared to a homogeneous NP distribution. These combined simulation and experimental data provide first evidence for optimising MRT through the incorporation of newly observed Ta 2 O 5 NP distributions within 9L cancer cells.
Introduction
Cancer remains one of the leading causes of death worldwide. Amongst other treatment methods, such as surgery and chemotherapy, the use of radiation in the treatment of cancer remains the most prominent and successful modality [1] . The sensitive treatment of brain tumours (such as inoperable gliomas and gliosarcomas), with wide, and unsegmented radiotherapeutic beams, impart unavoidable yet clinically unacceptable damage to vital central nervous system (CNS) tissues [2, 3] . Microbeam radiation therapy (MRT) may provide a solution to this challenge.
MRT involves the application of an array of spatially fractionated microbeams sourced from third generation synchrotrons, with beam widths ranging from 25 to 75 µm, and a pitch of 200-400 µm [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
The energy of these beams lie within the kilovoltage X-ray range of 50-175 keV, as first outlined by Slatkin et al. [4] . Microbeam peak doses of between 500-1000 Gy can be delivered safely due to the wellknown dose volume effect [5] [6] [7] [8] .
The treatment quality of MRT is assessed by the peak-to-valley dose ratio (PVDR), which describes the ratio between the in-beam dose to the out-of-beam dose at mid distance between two adjacent microbeams. The peak doses are typically 20-100 times higher than the valley [5, 6, 7] . Small PVDRs indicate that the valley dose between adjacent microbeams, is large in relation to the peak dose. When made comparable to the large peak doses, this indicates better tumour coverage [7, 8] . Conversely, a large PVDR and small valley dose may be more accommodating for tissue recovery, allowing normal tissue to be spared through the dose-volume effect [5] [6] [7] [8] .
The key advantage of MRT arises from the reported increase in sensitivity of tumour tissue to the microbeam array, which differs to the observed recovery of normal tissue [9] [10] [11] [12] [13] [14] [15] [16] [17] . Radiation treatments for radioresistant tumours such as gliomas, require extremely high absorbed doses [15, 16] , yet with their development in sensitive brain tissue, large doses cannot be administered without significant damage.
MRT becomes a preferable option as tumour control is maintained, and normal tissue can withstand high radiation doses when delivered in small volumes [9, 10] . Some pre-clinical trials note the development of minor cerebral oedemas following MRT [18] . However, the oedemas disappear within a week after the MRT treatment, in agreement with studies that highlight the success of normal tissue sparing with MRT [9] [10] [11] [12] [13] [14] [15] [16] [17] .
The effectiveness of MRT as a selective cancer treatment is yet to be understood completely. Radioresistant brain tumours, such as 9L gliosarcoma, are seen to be more effectively treated with MRT than broad beams due to large peak doses [15, 16] . Crosbie et al. [11] , indicates that there is a significant difference in the migration of tumour cells in comparison to the normal cells. This may increase the probability of cellular communications to initiate widespread apoptosis [12, 14] . This, and extreme damage to local tumour vasculature [13] , may provide a reason for the success of spatially fractionated beams to control radioresistant tumours. Therefore, the future applications of MRT are aimed at treating brain tumours. There is good prognosis for child brain cancers, with less risk of damage to the developing CNS than conventional broad beams [18] .
High-Z nanoparticles (NPs) have been shown to improve the effectiveness of dose conformity to tumour tissue in the case of conventional unsegmented kilovoltage X-rays [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . The advantages of NPs, besides the primary benefit of enhancing tumour radiosensitivity, often include biocompatibility, permeability to cell membranes due to their nano-scale dimensions, ability to specifically target certain tumours when coated and actively accumulate at tumour sites with leaky vasculature [21, 22] .
In MRT, NPs may be useful by raising the local dose to the tumour, in particular to enhance the low valley dose at the site of the tumour [7] . NP use may in turn promote more normal tissue sparing, as peak doses could be lowered to induce the same clinical treatment outcome. This potential has been demonstrated by Rahman et al. [27] , showing that in the presence of gold NPs (GNPs), the necessary dose delivered by MRT to kill endothelial cells can be reduced by 10 Gy. Martínez-Rovira et al. [7] demonstrated through Geant4 simulations, that GNPs enhanced the valley dose and produce significant decreases in the PVDR at the site of the tumour. This translates in a reduced dose in the healthy tissue, limiting possible collateral effects.
Tantalum pentoxide (Ta 2 O 5 ) NPs are a non-toxic, nano-structured ceramic compound. Their use as a radiosensitizer was first reported by Brown et al. [28] in conventional X-ray radiotherapy. These nanostructured ceramic particles have different aggregation properties than inert metal NPs. In particular, they tend to form shell aggregates instead of distributing homogeneously in the medium, producing different physical dose enhancements [29] .
Geant4 simulations were performed by McKinnon et al. [29] to characterise the physical dose enhancement produced by different distributions of Ta 2 O 5 , as observed experimentally, for a 150 kVp broad beam. The shell structures produced large localised physical dose enhancements to surrounding cells using the kV broad beam, with large NP clusters up to 7 µm thick producing dose enhancement that is up to 100 times.
Because of the promising outcome obtained for conventional kV radiotherapy, Ta 
Motivation of the Geant4 simulation study: Experimental Measurements
This section summarises the first experimental measurements performed at the IMBL beamline of the Australian Synchrotron (AS) with tumorous 9L gliosarcoma cells and Ta 2 O 5 nanoparticles, motivating the Geant4 simulation study of this work. The details of the radiobiological experiments will be object of a separate article. Ta 2 O 5 NPs are nano-structured ceramic particles that have shown to enhance conventional kV and MV radiotherapy [29, 30] . Ta 2 O 5 NPs are manufactured according to Brown et al. [28] and added to the cell culture flask to incubate for 24 hours. The toxicity to the cells with concentrations of 50-500 µg/mL, after 24 hrs incubation, was found to be very low, with cell clonogenic survival of 80-100% [28, 30] . Therefore, there is no lethality towards cells besides that induced due to ionising radiation.
Besides this low-toxicity, Ta 2 O 5 NPs show great promise for treatments of these radio-resistant gliosarcomas, due to their inherent ability to internalise for long periods of time in 9L gliosarcoma. with a lower PVDR in the tumour and a higher PVDR in normal tissue [7, 8] , to maximise clinical benefits. NPs. Normalisation was done to the non-irradiated control.
Methodology: The Geant4 simulation study
Monte Carlo simulations were performed using Geant4, version 10.1 [31, 32] . The simulation set-up, shown in Fig keV, which is a typical energy range used for realistic MRT beams. The case of a 50 µm wide photon beam was considered, as it was the same width used in experimental studies.
In order to track secondary electrons down to 100 eV, and obtain shorter simulation execution times compared to the Geant4-DNA Low Energy Extensions, the Low Energy Electromagnetic Physics models based on PENELOPE [32] [33] [34] were adopted to describe particle interactions. Stewart et al. [33] showed that PENELOPE physics models can estimate physical quantities on the micron-scale between 1 and 25% 50 µm agreement with track structure Monte Carlo codes when calculating the mean specific energy. Auger electron emission and fluorescence are also modelled.
The physical dose enhancement in the cells of µ-phantom was studied by placing one shell-like Ta When the NP congregate was set in the peak position (at S8 in Fig. 3.1) , the dose was calculated by doubling the statistics derived from the cells in symmetric positions, with respect to the axis of the microbeam (corresponding to S1-S8 in Fig. 3.1 ). The NP congregate was then substituted by a homogeneous solution of the same NP mass distributed in the water medium of µ-phantom, outside the cells. The Ta 2 O 5 NP "shell" was modelled with thickness varying between 1 and 3 µm to reflect the average and maximum shell cluster thicknesses observed in experimental studies. The corresponding local NP concentrations in the µ-phantom, shown in Table 3 .1, are consistent with the order of magnitude of the concentrations of the experiments at the level of the cells, though only 1 shell is considered at a time. The second study consisted of calculating the dose enhancement, moving the NP shell congregate from the peak (position S8 in Fig. 3 .2) to the valley. In particular, the NP shell congregate was moved from the centre of the beam (P1) to the edge of the 50 µm beam (P2), the penumbral region (P3) and the valley region (P4). In this case, a 3 µm NP shell was modelled, as it produces the greatest amount of secondary electrons in photon interaction, due to its increased NP mass. In this set-up, the dose is calculated in each cell of the monolayer and averaged over the cells along each line (S1, S2, up to S15, see Fig. 3 .2), as there is no symmetry with NP dose enhancement in this set-up. 
Results

Dose enhancement with the nanoparticle shell located in the microbeam peak
The first study quantified the DER (defined in section 3) of the NP shell when it is located in the MRT peak (see Fig 3.1) , and the energy of the incident microbeam is varied. The dose was integrated over the peak region (indicated by a black rectangular contour in Fig. 3.1) . Fig. 4 Table 3 .
1). Statistical uncertainty is present, though smaller than plotted data points.
It can be observed that average DERs in the peak region range between 2 and 7 depending on microbeam energy and NP shell thickness. The thicker the shell, the higher the average DER. Although, the relative increase in DER is non-linear with respect to increasing shell thickness. Thicker shells produce more secondary electrons in the NP, however, at the same time, the number of electrons escaping the NP reduces because of the higher probability of ionisation interactions, which increase electron absorption in the NP itself. The interplay between the two effects leads to an increase in DER, but the DER increase becomes less efficient, eventually reaching a saturation effect as described in McKinnon et al. [29] .
The optimum DER is produced for incident photon energies between 40 and 60 keV, depending on the shell thickness. This energy correlates to a maximum in photon absorption relative to water for Ta 2 O 5 , shown in Figure 4 .2, which is dominant over the kV range.
The 67.4 keV K-edge [34] in Ta short-range, high LET photoelectrons. However, there is no increase of dose in the valley due to the limited range of the electrons.
At 150 keV, a higher dose in the valley at 100 µm from the peak is observed. This occurs because more energetic electrons are produced by the NP shell, which are able to reach the valley and contribute to the dose enhancement. Electrons with energy above 90 keV have a range in water larger than 100 µm, as shown in Table 4 .1, [35] . The DER increases with growing shell thickness, and this is also energy dependent. There is a (125 ± 10)% increase in the valley dose from a 1 µm to 3 µm NP shell with 150 keV beam, in contrast to 0% DER increase for the 50 keV beam. The rise in valley %DER with increasing shell thickness is due to the increase surface-to-volume ratio of the NP congregate.
The peak DER is largest with the lower energy beam, however, increasing the NP thickness results in a less efficient increase in the DER for 50 keV with respect to the 150 keV beam. This is because the NP shell is more likely to absorb the higher LET electrons produced by the low energy beam. When the NPs are distributed in a solution throughout the entire µ-phantom, the dose expectedly has no dependence on the congregation characteristics of the NP. This is reflected in the results of Fig. 4 .7. For a 50 keV photon beam, the NP shell causes a larger dose in the peak than the corresponding homogeneous distribution because of the more localised dose enhancement in the peak and proximity to a greater density of NPs. When increasing the distance from the beam centre, the dose produced by the solution becomes larger than in the NP shell case. This occurs because secondary electrons can be produced throughout the µ-phantom due to the many NP targets, contributing to the dose locally at the point of generation. As a result, the DER produced by a NP solution is larger than the DER obtained with the NP shell located in the microbeam peak (see Fig. 4.8 ).
Dose enhancement when the nanoparticle is set in the microbeam valley
When the microbeam energy is lower (below 70 keV), a NP shell located in the valley produces a higher local DER than a homogeneous NP distribution due to enhanced local emission of high LET electrons depositing energy locally in the valley.
(A) (B)
Figure 4.7: Physical dose per incident photon with respect to distance from the centre of the microbeam for NPs distributed as a 3 µm shell in the peak (A) and in the valley (B), compared to NPs distributed homogeneously (15.6 mg/mL concentration) with selected incident photon energies (50 and 150 keV).
(A) (B) When the microbeam has a higher energy, such as 150 keV, the dose and the DER of a NP shell set in the peak are higher than the configuration of homogeneous solution. This occurs because the NP shell produces long-range dose enhancement and the probability of interaction with NPs located in the path of the incident beam is maximised with respect to the NP solution. When, instead, the NP shell is located in the valley, the associated dose and DER are similar to the homogeneous solution. This happens because the microbeam has lower probability of interaction with the NP shell when it is located in the valley.
MRT peak to valley dose ratio with Ta 2 O 5 nanoparticles
The peak-to-valley dose ratio (PVDR) is often used as an indication of the quality of a MRT treatment [4] . In this study, we have evaluated the PVDR for the case with and without NPs. with the NP shell set in the MRT peak or valley. A shell thickness of 3 µm was selected to obtain higher DER.
The PVDR was measured for locations P1-4 as shown in Fig. 3 .2. For any photon beam energy, the PVDR is largest and smallest when the NP shell is located in the centre of the beam and in the valley, respectively as shown in Fig. 4 .9. This is due to the interplay between the probability of interaction of the NPs with the incident beam (which is expectedly greater in the peak), and the kinetic energy spectra of the secondary electrons produced. Overall, the PVDR decreases when the NP shell is placed further from the peak with respect to water.
The largest PVDR in water is obtained for lower beam energies, due to the short-range photoelectrons produced in the peak that do not reach the valley. This indicates the greatest potential for tissue sparing, with overall low valley doses relative to the peak. There is also highly localised dose enhancement obtained at low beam energies with NP shells, as shown in Fig. 4 .6A. Therefore, the PVDR is larger than the one calculated for water when the NP is located in the peak, and smaller when the NP shell is located in the valley.
When instead the NP shell is set in the valley, the PVDR is always lower with respect to the case of a homogeneous solution, except at 150 keV, where instead the PVDRs are similar.
The PVDR calculated with the NP distributed homogeneously was found to always be equal to, or less than the PVDR calculated in water without NPs, in agreement with Martinez-Rovira et al. [5] . This occurs because secondary electrons can be produced in the NP material located throughout the entire µ-phantom, including the valley, and results in a reduction in the PVDR.
The PVDR calculated with the NP solution is therefore always lower than the PVDR calculated with the NP shell set in the peak, for any energy of the incident photon beam.
These results emphasize how the congregation properties of NPs play a crucial role in determining the PVDR. 
Discussion and conclusion
This study investigated the physical dose enhancement produced by Ta 2 O 5 NP shells in MRT using a simplified configuration, where one single NP congregation was located in different positions in the MRT peak and valley, and compared to homogeneously distributed NPs. This study showed that NP dose enhancement for SMART is highly dependent on the NP congregation properties, location of congregations with respect to the beam peak, and photon energy.
The NP dose enhancement was found to increase with the NP shell thickness because of the higher probability of generating secondary photoelectrons, and was found to be dependent on the energy of the incident photon beam, as expected. In the case of a photon beam below 70 keV, the DER is mainly localised to the NPs, and in particular the cell nucleus surrounded by the NP shell and in the adjacent cell nuclei. When the photon beam energy increases, there are long-range effects, producing significant dose enhancement at some distance from the NP, due to the greater range of secondary electrons.
The DER is maximised for lower photon energies because of the increase in the photoelectric effect cross-section. The maximum DER obtained with a 50 keV photon beam is approximately 45 when the NP is located in the MRT peak. With the NP shell located in the valley, the maximum DER was similar at 52. With the NP shell is located in the valley, the DER in the valley is generally much higher with low energy beams because of the localised energy deposition. As a result, the PVDR has its minimum in this configuration, and only approaches the PVDR without NPs when the beam energy increases.
Overall, the NP shell proved to be useful in enhancing the dose to the population of cells over a large range of beam energies when located either in the MRT peak or in the valley. A homogeneous NP solution showed a less variable DER throughout the µ-phantom and across all microbeam energies with respect to the NP shell, as expected, because of the uniform distribution of NPs in the medium. The NP homogeneous solution produces a lower PVDR than the case without NPs, across all energies. Table 5 .1 summarises the doses in the peak and valley for a set of NP congregation properties and
energies. These results demonstrate that the NP distribution properties are crucial in determining the dose enhancement ratio and PVDR, and therefore must be taken into account to optimise the MRT treatment with NPs. The highest valley dose is produced with a NP shell in the valley at low energies.
This is followed by 150 keV beam incident on a NP shell to produce significant NP dose enhancement, independently from the location of the NP shell with respect to the microbeam. The NP homogeneous distribution tends to increase the valley dose at least two-fold for any MRT energy considered. The results of this study indicate that both the NP distribution and microbeam energy must be considered for efficient NP dose enhancement. MRT beams with energy range below the K-edge of Ta (~70 keV), may be adopted to reduce collateral effects to healthy tissues, due to the largest PVDR in water.
Furthermore, the significant local dose enhancements produced by selective NP shells in tumour cells via the increased production of higher LET electrons, give good prognosis for tumour control. With a selective internalisation in the tumour cells, higher target doses may be delivered to the tumour, which is beneficial for effective treatment of radioresistant cancers [5, 16, 17] .
Another possible solution is to instead adopt a higher energy photon beam (above ~ 100 keV), which reduces the PVDR with NPs both homogeneously distributed and with NP shells. This solution may be more beneficial to achieve a better coverage of the tumour, particularly for homogeneous NP distributions, while eventually reducing the overall dose administered to the patient.
In order to further investigate the optimal energy of the photon beam, future simulation work will investigate the DER and PVDR in a more realistic scenario in terms of shell distribution throughout the entire cell population. The effect of multiple microbeams will be investigated as well as the effect of different peak-to-peak spacing and beam widths. The simulation study will be integrated with radiobiological measurements at the AS using low microbeam energies to quantify NP sensitisation.
Furthermore, the selectivity of internalisation of NP shells will be investigated.
